mendous burden to society and results in a greater number of years of potential life lost (YPLL) than any other human disease. Novel lifesaving therapies in trauma and critical care are clearly an unmet medical need. Victims of trauma who survive the initial injury often suffer from multiple secondary consequences including wound infections, acute lung injury/acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), neurocognitive dysfunction after traumatic brain injury (TBI), and paralysis after spinal cord injury (SCI). Aside from supportive care, there are few if any interventions that significantly reduce the morbidity and mortality of these conditions. This is an area of medicine with limited therapeutic options and unlimited scope for advancement. Relevant to combat casualty care, it is clear that many of the wounded warriors who have suffered battlefield injuries are in dire need of reparative and regenerative therapies after they survive the initial injury. The same is true of civilian trauma.
An emerging area of investigation that has generated considerable attention and interest over the past 10 years is the use of cellular therapies (CT) to prevent damage and promote repair of injured tissue in trauma and critical care applications. 2 Cell-based therapies provide a viable approach to improving outcomes in critically injured patients. The utilization of CT in trauma actually began long before endeavors in stem cell therapies or regenerative medicine, with the transfusion of whole blood in exsanguinating patients. Before the concept of stem cell therapies and prior to component-based blood transfusion, transfusion of whole blood was indeed the first cell therapy to be clinically utilized. The first trauma patient to receive a blood transfusion in the United States dates back to the Civil War (1861-1865), where hemorrhage caused three-fourths of the deaths. 3 In recent years, the field of CT and regenerative medicine has grown and generated global excitement over the potential to address many different types of diseases. In trauma and critical care applications, CT is being investigated for both the acute and chronic phases of injury. 2, 4 Although the field is still in its early stages of development, animal and human studies demonstrate the promise of CT for trauma-induced conditions such as TBI, SCI, organ failure (ARDS, AKI), orthopedic trauma, burns, and ischemia/reperfusion insults.
This supplement in the journal TRANSFUSION selects a group of papers that are focused on speaker topics presented at the biannual conference Cellular Therapies in Trauma and Critical Care Medicine (CTTACC). This supplement was generated from the third CTTACC conference that took place in San Francisco, California, in 2017. The primary goal and laser focus of CTTACC is to accelerate and advance the translation of CT and novel blood products, two of the most rapidly developing areas in transfusion medicine, to trauma patients. The topics selected for this supplement are focused on the translation of novel therapeutics, novel blood products, and CT to trauma and critical care patients. Both areas of investigation have similar challenges in research, development, and translation to patients, and are key future directions for transfusion medicine as a field.
In the first paper, Ness and Gehring outline the history and challenges of whole blood transfusion versus blood component-based transfusion. There has recently been an impetus to move back toward whole-blood transfusion with data suggesting that low-titer O+ whole blood may be an advantageous and viable possibility to attenuate bleeding and replace shed blood in bleeding patients. 5 Returning to the practice of transfusing whole blood goes against current transfusion practice and the blood banking community's thoughts on the superiority of blood component based transfusion. Ness and Gehring speculate the statements on whole blood's inadequacies are an example of "alternate facts" demonstrating that clinical transfusion practices and current dogma have often been established without solid clinical data to back up the benefit to the patient. Complementary to the paper by Ness and Gehring is the paper on the challenges of developing and bringing a novel blood product, specifically dried plasma, to clinic. Buckley and Gonzalez outline the odyssey to produce and gain regulatory approval for a dried, lyophilized plasma product in the United States. If a dried plasma product were commercially available in the United States, it would change blood banking practice as we know it. It would alter the availability of plasma for bleeding patients in civilian and military settings and also likely save countless lives, especially in remote or austere settings where blood products are not readily available. Ironically, as Buckley and Gonzalez note, dried plasma was an approved product utilized during World War II by the United States but fell out of practice for safety reasons that are currently solvable. The bumpy road for a lyophilized plasma product, from a preclinical, regulatory, and clinical standpoint, is one that likely lies ahead for CT, and much can be learned and applied from one field to the other. In line with the development of novel products for trauma and critical care medicine is the need for an understanding of the barriers that exist in testing novel products in trauma patients. Miskimin and colleagues discuss the translational barriers that arise in trauma trials ranging from disease heterogeneity, selecting the right outcome measures, powering studies adequately, effective trial design, cost, and issues pertaining to exception from informed consent (EFIC) in trauma patients for prehospital and early inhospital studies. The paper by Cox and colleagues also outlines the trials and tribulations of clinical studies specifically in the area of TBI. Despite multiple attempts and vast preclinical support for efficacy, there has not been a single therapeutic to date that has demonstrated significant efficacy in mitigating outcomes in TBI. 6 One of the main challenges has been disease heterogeneity and defining clinically meaningful outcome measures in TBI patients. Cox and colleagues describe their endeavors to establish physiologically relevant outcome measures and imaging-based outcomes for TBI that are linked to the CT mechanisms of action, which subsequently increase the probability of detecting the therapeutic effect of the cell product tested. Resolving and understanding issues with clinical trials in trauma are critical to the survival of the field of CT or any novel product in trauma. Attention needs to be given by all stakeholders involved-industry, academia, and funders-to ensure that careful thought has gone into the trial design and selection of the appropriate target cohorts of patients for the product being tested. In terms of barriers in translation to trauma of novel CT products, one of the often overlooked and neglected areas, that can completely alter the outcome and success of the trial, is the quality and characteristics of the cell product itself. Stroncek and colleagues have described in their paper the translational challenges of producing a cellular therapeutic for clinical applications. The challenges that exist in the field to date include issues with large-scale production of high-quality and potent cell doses, effective cryopreservation techniques, and long-term storage of doses. As the field advances, awareness of the importance of optimizing cell quality, production, and storage has moved to the forefront in translation of CT to clinical medicine.
This supplement also includes reviews of cutting-edge research in the areas of critical care medicine and CT, specifically ARDS. Huppert and colleagues describe preclinical and clinical efforts investigating the therapeutic potential of mesenchymal stem cells (MSCs) in the treatment of ARDS. To date, MSCs have been demonstrated to be safe in hundreds of clinical trials listed on ClinicalTrials.gov and MSCs will likely be the first non-autologous CT commercialized in the United States for clinical application in graft-versus-host disease (GVHD). Currently, there is a trial under way for MSCs in ARDS that includes trauma patients with the final results still pending.
MSCs are a cell type that has been mechanistically shown to have potent anti-inflammatory and vascular stabilizing effects through the secretion of soluble paracrine factors including extracellular vesicles. In this supplement, Lee and colleagues summarize the preclinical studies testing MSC extracellular vesicles (EVs) as a treatment for ARDS and other inflammatory lung diseases, suggesting that perhaps we do not need the cells but can consider using MSC EVs as a "cell-free" therapeutic instead. These will be upcoming areas of development in the field of CT for trauma.
Inherent to traumatic injury is the ischemic insult and damage that ensues in injured tissue. The field of CT has focused preclinical and clinical research efforts on regenerative areas that greatly impact the course of patients inhospital and after discharge. In their review, Jones and colleagues describe the potential of using stem cells to promote wound healing, enhance regenerative healing, and minimize scarring. Current options for wound healing and minimizing organ fibrosis are discussed. These are critical points for trauma victims who survive the initial injury but have sustained considerable tissue and organ injuries that significantly impact their quality of life. Fierro and colleagues also describe the possibility of utilizing gene-modified MSCs to support wound healing and revascularization of injured tissues. These studies reveal the possibility of creating specialized types of cells that are modified to produce healing factors that are application specific.
In summary, the papers in this TRANSFUSION supplement represent the gist of topics covered during the 2017 CTTACC conference. The main motivation and goal of the CTTACC conference is to educate, facilitate collaboration, and advance the investigation of CT and novel products in trauma and critical care medicine. CTTACC facilitates translation to patients by bringing together the multidisciplinary expertise and input of blood bankers, basic scientists, and clinicians coordinating trials, along with industry and regulatory bodies (Biomedical Advanced Research and Development Authority, National Institutes of Health, Department of Defense, AABB, California Institute for Regenerative Medicine, and the Food and Drug Administration). The ultimate goal of CTTACC is to forge new collaborations, discuss existing barriers in translation, and understand the complexities of treating critically injured trauma patients. CT and novel blood products in trauma are areas that hold great promise for the severely injured trauma patient; however, there is currently no clear logistical and regulatory road map to translate these products to patients, and hence endeavors in this area of research require focused thought and effort to advance the field. The next CTTACC meeting is planned for December 11-13, 2019 in San Diego, California.
